XOMA - Xoma to pay $1M to LadRx as rare disease therapy undergoes FDA review
2024-01-12 07:44:58 ET
More on LadRx, XOMA, etc.
- XOMA Preferreds: I Upped My Rating On One Preferred Stock To A Buy
- Xoma appoints Owen Hughes as CEO, Jack Wyszomierski as chairman
- XOMA gets $5M milestone upon FDA's acceptance of Day One's Tovorafenib NDA
- Financial information for LadRx Corporation
- Seeking Alpha’s Quant Rating on XOMA
For further details see:
Xoma to pay $1M to LadRx as rare disease therapy undergoes FDA review